written on 24.04.2014

AstraZeneca CEO jumps into asset-sale fray to 'focus on what we do well'


In announcing first-quarter earnings Thursday, AstraZeneca CEO Pascal Soriot sounded as if he'd been reading the deluge of trend stories analyzing pharma's latest spate of M&A. In fact, he's ready to participate, with a couple of sales/spinoffs together worth about $15 billion, according to analysts